Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amitriptyline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 6/20 | 1.00 |
| ▸ | HRH1 | P35367 | 8/20 | 1.00 |
| ▸ | HTR2B | P41595 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | DRD2 | P14416 | 6/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 6/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 6/20 | 1.00 |
| ▸ | HTR2C | P28335 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amitriptyline SCHEMBL7824 | 1.00 | SLC6A2 (1.00) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL2877708 | 1.00 | SLC6A2 (1.00) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL28299765 | 0.98 | SLC6A2 (0.97) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL41079 | 0.98 | SLC6A2 (1.00) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL7215255 | 0.98 | SLC6A2 (0.97) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL29356807 | 0.98 | SLC6A2 (1.00) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL14937172 | 0.98 | SLC6A2 (1.00) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL3055149 | 0.97 | SLC6A2 (0.94) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL14918734 | 0.97 | SLC6A2 (0.97) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL7214653 | 0.91 | SLC6A2 (0.83) | SLC6A2HRH1HTR2BKCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264436-A1 | PREDICTING RESPONSES TO PREVENTIVE MEDICATIONS WITH MACHINE LEARNING MODELS BASED ON PATIENT AND HEADACHE FEATURES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250120962-A1 | NONSELECTIVE METABOTROPIC GLUTAMATE RECEPTOR ACTIVATORS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND 22Q SYNDROME | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-04-17 | — | — | US | claimed |
| EP-3551182-B1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B V (NL) | 2025-03-19 | — | — | EP | claimed |
| EP-3508501-B1 | USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS | H LUNDBECK AS (DK) | 2024-11-06 | — | — | EP | claimed |
| WO-2024189252-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S.A. (ES) | 2024-09-19 | — | — | WO | claimed |
| EP-3630102-B1 | FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER | GLYTECH LLC (US) | 2024-08-14 | — | — | EP | claimed |
| EP-3192499-B1 | CELLULOSE FIBRE BASED SUPPORT MATRICES FOR LAYERED PRODUCTS FOR ORAL AND PERORAL APPLICATION AND THEIR PREPARATION | GLATT GMBH (DE) | 2023-11-29 | — | — | EP | claimed |
| EP-3999036-B1 | ORODISPERSIBLE POWDER COMPOSITION COMPRISING A TRIPTAN | BIOPHARMA SYNERGIES S L (ES) | 2023-11-08 | — | — | EP | claimed |
| EP-4255448-A1 | ALCOHOL-BASED PRODUCT ENABLING TO DISINFECT THE SKIN AND SUPPORTING THE SKIN FLORA | Eczacibasi Tüketim Ürünleri Sanayi Ve Ticaret Anonim Sirketi (TR) | 2023-10-11 | — | — | EP | claimed |
| WO-2023133573-A1 | METHODS AND SYSTEMS FOR TREATING CHRONIC PAIN CONDITIONS USING DIGITAL THERAPEUTICS IN COMBINATION WITH OTHER THERAPIES | Mahana Therapeutics, Inc. (US) | 2023-07-13 | — | — | WO | claimed |
| EP-4159196-A1 | TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST L AMITRIPTYLINE FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN FROM THE PHANTOM LIMB | Algotherapeutix (FR) | 2023-04-05 | — | — | EP | claimed |
| EP-4159195-A1 | TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST AMITRIPTYLINE FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN INDUCED BY A CORONAVIRUS | Algotherapeutix (FR) | 2023-04-05 | — | — | EP | claimed |
| EP-4033581-A1 | IONIC LIQUIDS FOR USE AS ADDITIVE FOR A LITHIUM-ION BATTERY | High Tech Battery Inc. (TW) | 2022-07-27 | — | — | EP | claimed |
| WO-2022119532-A1 | ALCOHOL-BASED PRODUCT ENABLING TO DISINFECT THE SKIN AND SUPPORTING THE SKIN FLORA | ECZACIBASI TUKETIM URUNLERI SANAYI VE TICARET ANONIM SIRKETI (TR) | 2022-06-09 | — | — | WO | claimed |
| WO-2026102455-A1 | LIPID NANOPARTICLE COMPOSITIONS FOR MICRONEEDLE-BASED TRANSDERMAL DELIVERY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4741827-A2 | DESORPTION ELECTROSPRAY IONISATION MASS SPECTROMETRY (\"DESI-MS\") AND DESORPTION ELECTROFLOW FOCUSING IONISATION (\"DEFFI-MS\") ANALYSIS OF BIOLOGICAL SAMPLES ON SWABS | Micromass UK Limited (GB) | 2026-05-13 | — | — | EP | disclosed |
| US-20260117203-A1 | MUTANT KETOREDUCTASE WITH INCREASED KETOREDUCTASE ACTIVITY AS WELL AS METHODS AND USES INVOLVING THE SAME | HOFFMANN LA ROCHE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3952873-A1 | A CLASS OF SMALL-MOLECULE COMPOUNDS AND THEIR PRODRUGS FOR INTERVENTION WITH CAMK2A, AND THEIR USE IN ACUTE BRAIN INJURIES AND CENTRAL HYPERSOMNIAS | Københavns Universitet (DK) | 2022-02-16 | — | — | EP | disclosed |
| US-11239066-B2 | Cell population analysis | MICROMASS UK LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| EP-3943072-A1 | DRUG LOADED NANORESIN PARTICLES | Sun Pharma Advanced Research Company Ltd (IN) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120962-A1 | NONSELECTIVE METABOTROPIC GLUTAMATE RECEPTOR ACTIVATORS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND 22Q SYNDROME | GRM2, GRM6, GRM4 | SLC6A2 69/4885SLC6A4 33/4885HRH1 2360/4885 |
| US-20260117203-A1 | MUTANT KETOREDUCTASE WITH INCREASED KETOREDUCTASE ACTIVITY AS WELL AS METHODS AND USES INVOLVING THE SAME | TKT, PRKDC, CHAMP1 | SLC6A2 2767/4885SLC6A4 2318/4885HRH1 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.